# Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

> **NCT05124002** · PHASE4 · UNKNOWN · sponsor: **Beijing Tsinghua Chang Gung Hospital** · enrollment: 66 (estimated)

## Conditions studied

- Cholangiocarcinoma, Intrahepatic

## Interventions

- **DRUG:** Recombinant Human Adenovirus Type 5
- **DRUG:** HAIC of FOLFOX

## Key facts

- **NCT ID:** NCT05124002
- **Lead sponsor:** Beijing Tsinghua Chang Gung Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05124002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05124002, "Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05124002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*